MeSH D018357 - respiratory syncytial virus infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Ribavirin | Ribavirin | 2004-10-04 | |||
| Ribavirin | Ribavirin Teva | 2009-03-31 | ||||
| Ribavirin | Ribavirin Teva Pharma B.V | 2009-07-01 | ||||
| Mylan | Ribavirin | Ribavirin Mylan (previously Ribavirin Three Rivers) | 2010-06-10 | |||
| Roche | Ribavirin | Copegus | 2002-12-03 | |||
| Ribavirin, Peginterferon alfa-2a | Pegasys Copegus | 2004-06-04 | ||||
| Sandoz | Ribavirin | Ribavirin | 2006-10-03 | |||
| AstraZeneca | Palivizumab | Synagis | 1999-08-13 | $226 M | Q2/21-Q2/24 | |
| Bausch Health Companies | Ribavirin | Virazole | 1985-12-31 | |||
| Merck & Co | Ribavirin | Cotronak | 1999-05-07 | |||
| Ribavirin, Peginterferon alfa-2b | PegIntron/ Rebetol Combo Pack | 2008-06-13 | ||||
| Ribavirin | Rebetol | 1998-06-03 | ||||
| Aurobindo Pharma | Ribavirin | Ribavirin | 2009-09-17 | |||
| Zydus Therapeutics | Ribavirin | Ribavirin | 2005-12-05 | |||
| Chartwell Pharmaceuticals | Ribavirin | Ribasphere | 2004-04-06 | |||
| Ribavirin | Ribavirin | 2004-04-06 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
44%4/9
Phase 2
83%5/6
Phase 3
63%5/8
Approved: 3Overall Success rate: 23%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use